Alternative Names
CLMF antibody; CLMF p35 antibody; CLMF p40 antibody; CLMF1 antibody; CLMF2 antibody; Cytotoxic lymphocyte maturation factor 1, p35 antibody; Cytotoxic lymphocyte maturation factor 2 antibody; Cytotoxic lymphocyte maturation factor 35 kDa subunit antibody; Cytotoxic lymphocyte maturation factor 40 kDa subunit antibody; IL 12A antibody; IL 2 subunit p40 antibody; IL-12 subunit p35 antibody; IL-12A antibody; IL-12B antibody; IL12 antibody; IL12, p35 subunit antibody; IL12, subunit p40 antibody; IL12A antibody; IL12A_HUMAN antibody; IL12B antibody; IL35 subunit antibody; Interleukin 12 alpha chain antibody; Interleukin 12 beta chain antibody; Interleukin 12 subunit beta antibody; Interleukin 12, p40 antibody; Interleukin 12A;natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35 antibody; Interleukin 12B;natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40 antibody; Interleukin 12B antibody; Interleukin-12 subunit alpha antibody; Natural killer cell stimulatory factor 1, 35 kD subunit antibody; natural killer cell stimulatory factor 2 antibody; Natural killer cell stimulatory factor, 40 kD subunit antibody; NF cell stimulatory factor chain 1 antibody; NFSK antibody; NK cell stimulatory factor chain 1 antibody; NK cell stimulatory factor chain 2 antibody; NKSF antibody; NKSF1 antibody; NKSF2 antibody; P35 antibody; briakinumab
Immunogen
Recombinant Human IL12A protein
Immunogen Species
Homo sapiens (Human)
Concentration
It differs from different batches. Please contact us to confirm it.
Form
Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
In stock
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
Description
This recombinant monoclonal antibody is developed as a research-grade biosimilar to briakinumab, targeting IL12A (interleukin-12 subunit alpha), also known as IL-12p35. IL12A encodes a critical subunit shared by both IL-12 and IL-23, two heterodimeric cytokines that play pivotal roles in regulating T-helper cell differentiation and inflammatory immune responses. IL-12 promotes Th1 cell development and interferon-gamma production, while IL-23 is essential for Th17 cell maintenance and function. Dysregulation of IL12A-containing cytokines has been implicated in various autoimmune and inflammatory conditions, including psoriasis, inflammatory bowel disease, and multiple sclerosis, making it an important therapeutic target.
Briakinumab was originally developed as a human monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23, showing promising efficacy in clinical trials for moderate-to-severe plaque psoriasis. This biosimilar antibody provides researchers with a valuable tool for investigating IL-12/IL-23 signaling pathways, studying immune-mediated inflammatory mechanisms, and exploring potential therapeutic interventions in autoimmune disease models.